Please try another search
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Name | Age | Since | Title |
---|---|---|---|
Sukumar Nagendran | 55 | 2020 | President, Head of Research & Development and Director |
Sean P. Nolan | 54 | 2020 | CEO & Chairman |
Phillip B. Donenberg | 62 | 2020 | Independent Director |
Deborah Bilder | - | 2021 | Independent Scientific Advisory Board |
Paul B. Manning | 67 | 2020 | Board Observer |
Laura Sepp-Lorenzino | 62 | 2020 | Independent Director |
Sean Stalfort | 53 | 2023 | Independent Director |
Benedikt Schoser | - | 2021 | Member of Independent Scientific Advisory Board |
Alison Long | 61 | 2023 | Independent Director |
David P. Dimmock | - | 2021 | Independent Scientific Advisory Board |
Gerald S. Lipshutz | - | 2021 | Independent Scientific Advisory Board |
Wendy K. Chung | 54 | 2021 | Independent Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review